Iff, Joel http://orcid.org/0000-0002-1102-0651
Carmichael, Chloe
McKee, Stephanie
Sehinovych, Ihor
McNeill, Carolyn
Tesi-Rocha, Carolina
Henricson, Erik
Muntoni, Francesco
Kitchen, Helen
Funding for this research was provided by:
Sarepta Therapeutics
Article History
Received: 4 March 2024
Accepted: 28 May 2024
First Online: 3 July 2024
Declarations
:
: Joel Iff, Ihor Sehinovych, and Carolyn McNeill are employees of Sarepta Therapeutics, Inc., and may hold stock/options. Chloe Carmichael, Stephanie McKee, and Helen Kitchen are employees and stockholders of Clarivate, a healthcare research company that provides consultancy to pharmaceutical companies, including Sarepta Therapeutics, Inc. Carolina Tesi-Rocha reports consulting fees (Avexis, Biogen, Sarepta Therapeutics, Inc., Novartis, NS Pharma) and is a site investigator for clinical trials: Avexis, Biogen, Cytokinetics, Genzyme, Pfizer, PTC Therapeutics, Roche, Sarepta Therapeutics, Inc., Scholar Rock, and Janssen. Erik Henricson has received consulting fees from Sarepta Therapeutics, Inc., Santhera Pharmaceuticals, Pfizer, Eprirum Bio, Capricor, Catabasis, Mallinkrodt, Bristol-Myers Squibb, PTC Therapeutics, PepGen, and GSK and has received speaker honoraria from Parent Project Muscular Dystrophy, Muscular Dystrophy Association, and ENMC. Francesco Muntoni has received consultant fees and speaker honoraria from Sarepta Therapeutics, Inc. He is a member of the Pfizer SAB and, relevant for DMD, has received consultancies from Dyne Therapeutics, Roche, and PTC Therapeutics.
: This study was performed in line with the principles of the Declaration of Helsinki. The study was reviewed and approved by New England Independent Review Board (NEIRB [now part of WCG-IRB] number 20203393).